No Data
No Data
B.Riley Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $37
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
B. Riley Securities Initiates Coverage On ArriVent BioPharma With Buy Rating, Announces Price Target of $37
ArriVent BioPharma Initiated at Buy by Guggenheim
Guggenheim Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $45